Maximizing Innovation Incentives: How the Orphan Drug Credit Can Outperform the R&D Tax Credit

The Orphan Drug Credit (ODC) is a powerful federal tax incentive designed to encourage the development of treatments for rare diseases, generally defined as conditions affecting fewer than 200,000 individuals in the United States. For biotechnology and pharmaceutical companies advancing therapies through clinical trials, the ODC can deliver a significantly enhanced tax benefit compared to the traditional Research & Development (R&D) Tax Credit for the same categories of expenses.

Understanding the Opportunity

The ODC is available for qualified clinical testing expenses incurred after a drug receives FDA orphan designation. This timing is critical; while early-stage research may fall under the R&D Tax Credit, the most capital-intensive phase of development (human clinical trials) often becomes eligible for the ODC.

Qualified expenses generally include:

The credit equals 25% of qualified clinical trial expenditures, providing a substantial incentive during one of the most resource-intensive phases of drug development to offset federal income tax liability dollar-for-dollar.

ODC vs. R&D Tax Credit: Why ODC Often Delivers Greater Value

While both credits are designed to reward innovation, they differ significantly in how benefits are calculated and applied to clinical trial costs.

1. Higher Credit Rate on the Same Expense Base

The most immediate advantage of the ODC is its flat 25% credit rate on qualified clinical trial expenses.

By comparison, the R&D Tax Credit typically generates a benefit of approximately 6%–10% of eligible costs, depending on methodology and taxpayer profile.

For expenses related to human clinical trials, the ODC can produce a materially larger dollar-for-dollar benefit. Expenses not eligible for the Orphan Drug Credit may still be used to generate an R&D Tax Credit, allowing companies to benefit from both incentives within the same tax year.

2. More Favorable Treatment of Contract Research Costs

Clinical trials are often heavily outsourced to CROs and third-party providers. While both credits allow for contractor costs, the ODC framework is generally more aligned with full-scale clinical outsourcing models, allowing a broader and more direct capture of these costs.

Companies with significant third-party clinical spend often see a higher effective credit yield under the ODC compared to the R&D credit, which applies limitations to contractor cost inclusion.

3. Designed for the Highest-Cost Phase of Development

The R&D Tax Credit broadly applies across the innovation lifecycle, including early-stage experimentation and process development.
The ODC, however, is specifically targeted at clinical trials, which are typically the most expensive and risky phase of drug development.

4. Strategic Expense Allocation Drives Maximum Value

Although companies cannot claim both credits on the same expenses, they can strategically allocate costs to maximize total tax benefits:

This coordinated approach ensures that each dollar of spend is matched to the most advantageous incentive available.

Key Considerations and Compliance

The IRS expects a high level of documentation to support ODC claims. Companies should maintain:

As with the R&D Tax Credit, audit-ready documentation is essential to sustain the benefit and mitigate risk.

The Bottom Line

For companies developing orphan-designated therapies, the Orphan Drug Credit is often significantly more valuable than the R&D Tax Credit when applied to clinical trial expenditures. Its higher credit rate, favorable treatment of clinical costs and alignment with late-stage development make it a critical planning opportunity.

When properly coordinated with the R&D Tax Credit, companies can maximize incentives across the full innovation lifecycle, capturing meaningful tax savings from early research through commercialization.

How Withum Can Help

Withum’s R&D Tax Credit Services Team brings deep experience in both R&D and Orphan Drug Credit studies. Our approach focuses on:

If your organization is investing in rare disease therapies or preparing for clinical trials, we would welcome the opportunity to perform a complimentary assessment and help you maximize available incentives.